Premature Ejaculation Market

Market Overview:

The 7 major premature ejaculation markets reached a value of US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.3 Billion by 2034, exhibiting a growth rate (CAGR) of 7.64% during 2024-2034.

The premature ejaculation market has been comprehensively analyzed in IMARC's new report titled "Premature Ejaculation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Premature ejaculation refers to a common sexual health concern that affects many men, characterized by the inability to control ejaculation during sexual activity. It is defined as the occurrence of ejaculation before or shortly after penetration, often leading to dissatisfaction for both partners. This condition may cause emotional distress, relationship strain, and reduced self-esteem. The symptoms of the illness include consistent ejaculation within first minute of penetration or even before penetration occurs. While occasional instances of early ejaculation might not necessarily indicate a problem, persistent and recurrent occurrences could point to the presence of the disease. Individuals suffering from the ailment might also experience psychological factors, such as stress, performance pressure, and anxiety. Diagnosing premature ejaculation involves a thorough medical history and a discussion of sexual habits with a healthcare provider. The Intravaginal Ejaculatory Latency Time (IELT) is commonly used as a quantitative measure, representing the time from penetration to ejaculation to confirm the diagnosis.

The increasing prevalence of various psychological factors associated with the ailment, such as early sexual experiences, sexual abuse, poor body image, depression, anxiety, etc., is primarily driving the premature ejaculation market. In addition to this, the rising incidence of irregular hormone levels, which affect rhythmic muscle contraction and regulate orgasm via peripheral, central, and spinal mechanisms, is also creating a positive outlook for the market. Moreover, the inflating application of effective medications, including selective serotonin reuptake inhibitors and topical anesthetics, to manage the condition and prolong ejaculation is further bolstering the market growth. Apart from this, the widespread adoption of counseling and sex therapy as viable approaches to address the emotional dimensions associated with premature ejaculation is acting as another significant growth-inducing factor. Additionally, the emerging popularity of behavioral techniques on account of their numerous advantages, like non-invasiveness, improved control over ejaculation timing, enhancing overall sexual satisfaction for both partners, etc., is also augmenting the market growth. Furthermore, the escalating demand for dorsal neurectomy procedures that involve cutting or removing a portion of the dorsal nerve responsible for transmitting sensory signals from the penis to the brain is expected to drive the premature ejaculation market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the premature ejaculation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for premature ejaculation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the premature ejaculation market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the premature ejaculation market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the premature ejaculation market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current premature ejaculation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the premature ejaculation market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the premature ejaculation market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the premature ejaculation market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of premature ejaculation across the seven major markets?
• What is the number of prevalent cases (2018-2034) of premature ejaculation by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of premature ejaculation by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with premature ejaculation across the seven major markets?
• What is the size of the premature ejaculation patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of premature ejaculation?
• What will be the growth rate of patients across the seven major markets?
   

Premature Ejaculation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for premature ejaculation drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the premature ejaculation market?
• What are the key regulatory events related to the premature ejaculation market?
• What is the structure of clinical trial landscape by status related to the premature ejaculation market?
• What is the structure of clinical trial landscape by phase related to the premature ejaculation market?
• What is the structure of clinical trial landscape by route of administration related to the premature ejaculation market?